Correlation between the expression profile of cytokeratin 19/glypican 3 and recurrence of hepatocellular carcinoma after interventional therapy
10.3760/cma.j.cn501113-20191227-00483
- VernacularTitle:细胞角蛋白19/磷脂酰肌醇蛋白聚糖3表达模式与肝细胞癌患者介入治疗后复发的相关性
- Author:
Xiu ZHENG
1
;
Chunwang YUAN
;
Xiongwei CUI
;
Fudong LYU
;
Dawei ZHAO
;
Honggang LIU
;
Jiliang FENG
Author Information
1. 首都医科大学附属北京佑安医院病理科 100069
- Keywords:
Hepatocellular carcinoma;
Liver cirrhosis;
Interventional therapy;
Cytokeratin19;
Glypican-3;
Milan criteria
- From:
Chinese Journal of Hepatology
2020;28(11):936-941
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the correlation between the expressions profile of cytokeratin 19/glypican 3 (CK19/GPC3) and recurrence of hepatocellular carcinoma after interventional therapy.Methods:Clinical and pathological information of 251 eligible cases with hepatocellular carcinoma who underwent interventional therapy in You'an Hospital from November 2007 to May 2016 were retrospectively collected. Univariate and multivariate Cox regression analysis was used to analyze the relevant risk factors that may affect their prognosis. Kaplan-Meier survival analysis was used to draw the survival curve. Log-rank test was used to compare the difference in survival rates between the groups.Results:Kaplan-Meier univariate analysis showed that histological grade, CK19/GPC3 expression profile, alpha-fetoprotein level and Hep Parl were closely related to tumor recurrence. Multivariate Cox regression analysis showed CK19/GPC3 expression profile ( HR = 1.634, 95% CI: 1.041 ~ 2.564, P = 0.033), histological grade ( HR = 1.445, 95% CI: 1.037 ~ 2.014, P = 0.030), alpha-fetoprotein level ( HR = 1.410, 95% CI: 1.042 ~ 1.908, P = 0.026), Hep Parl ( HR = 0.570, 95% CI: 0.349 ~ 0.930, P = 0.025) were the four independent factors for prediction of recurrence after interventional therapy. Conclusion:Hepatocellular carcinoma patients with CK19 +/GPC3 + and CK19 -/GPC3 + phenotypes who meet the Milan criteria have a higher risk of recurrence after interventional therapy than CK19 -/GPC3 - phenotypes.
